Tamoxifen Users Often Lack Required Eye Monitoring

Only 7% of patients get recommended eye exams, leaving many without necessary screening for potential vision changes.

Updated on Oct. 31, 2026 in Cancer

Flat gouache-painted editorial illustration of a high-precision medical lens, emphasizing the need for vision health monitoring in breast cancer patients. — A 2026 study reveals only 7% of tamoxifen users undergo recommended eye exams, highlighting a critical gap in breast cancer therapy monitoring. AI Illustration. Upload story photo >

Live Poll

Do you trust your doctor to advise you on necessary eye monitoring for new medications?

A June 2026 study found that only 7% of patients received an eye exam within a year of starting tamoxifen, a medication linked to potential retinal toxicity. Most patients prescribed this breast cancer therapy are not undergoing the specialized imaging often recommended for monitoring vision health.

Why it matters

Because tamoxifen can cause retinal damage and vision loss, experts stress that consistent monitoring is vital for early detection of eye complications. The current lack of formal screening guidelines may contribute to low follow-up rates for patients who do not have pre-existing eye conditions.

This retrospective study used data from the All of Us Research Program to track 5,136 individuals, finding that only 1.7% received retinal OCT or fundus photography after starting tamoxifen. Monitoring rates were significantly higher among patients with pre-existing glaucoma or diabetic retinopathy.

The players

All of Us Research Program

A National Institutes of Health initiative collecting health data from a diverse cohort of American participants to accelerate medical research.

The details

Tamoxifen is associated with crystalline retinopathy, a condition where drug deposits accumulate in the retina, potentially leading to visual impairment. Physicians typically rely on optical coherence tomography (OCT) or fundus photography to detect these changes before they become symptomatic. The analysis suggests that age and prior healthcare engagement are primary drivers of whether a patient receives an eye exam, rather than the initiation of the drug itself.

Ophthalmic encounter rates remained stable between 2000 and 2022.
Researchers analyzed the patient data during May and June 2026.

Health Landscape

The study sits at the intersection of oncology and ophthalmology, highlighting a gap in standard care protocols for common breast cancer treatments. It underscores the challenges of managing multi-organ toxicities when formal, unified screening guidelines for specific medications are absent.

If you are prescribed tamoxifen, ask your oncologist about the risk of retinal toxicity and whether you should establish a baseline eye exam with an ophthalmologist. It is worth discussing your specific medical history, especially if you have pre-existing conditions like glaucoma, to determine a personalized monitoring schedule.

The takeaway

While tamoxifen is an essential therapy, it requires proactive monitoring to protect your long-term eye health. Always keep a record of your medication history and be ready to ask your physician if a referral to an eye specialist is appropriate for your individual risk profile.